LPTX250117C5000
- 0.12
- +0.02+20.00%
Leap Therapeutics Newsroom
Catalyst Watch: Eyes on Electric Vehicle Deliveries, Retail Data and Housing Reads
Leap Announces Appointment of Jason Michaels as New CEO and Board Member
LEAP Awarded "Overall Practice Management Solution of the Year" Again by LegalTech Breakthrough
Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference
Buy Recommendation for Leap Therapeutics: Promising Phase 2 Trial Developments and Stable Financial Outlook
Leap Therapeutics | 8-K: Leap Therapeutics Reports Third Quarter 2024 Financial Results
Express News | Leap Therapeutics Q2 2024 GAAP EPS $(0.52) Misses $(0.43) Estimate
Leap Therapeutics: Cash Position Expected to Fund Operations Into 2Q 2026 >LPTX
Express News | Leap Therapeutics Q3 Operating Income USD -17.855 Million
Press Release: Leap Therapeutics Reports Third Quarter 2024 Financial Results
Leap Therapeutics 3Q Loss $18.2M >LPTX
Leap Therapeutics | 10-Q: Q3 2024 Earnings Report
Leap and Siro Unite to Unlock Total Sales Transparency With New Integration in SalesPro
Leap Therapeutics Completes Enrollment in Part B of DeFianCe Study
Express News | Leap Therapeutics Announces Completion of Enrollment in Part B of the Defiance Study of Dkn-01 for the Treatment of Colorectal Cancer Patients
Leap LLC Secures Spot on the Inc. 5000 Fastest-Growing Companies List for the Fourth Consecutive Year
Baird Maintains Leap Therapeutics(LPTX.US) With Buy Rating, Maintains Target Price $9
Optimistic Buy Rating on Leap Therapeutics Amid Promising Phase 2 Cancer Trial Outcomes
H.C. Wainwright Maintains Leap Therapeutics(LPTX.US) With Buy Rating, Maintains Target Price $5.5
Leap LLC Welcomes Jason Tillery as New Board Member: A Strategic Move to Enhance AI Capabilities